Daniel Chamié et al. Fernanda Oliveira Sérgio Braga José Ribamar Costa … Dimytri Alexandre Alvim de Siqueira Rodolfo Staico Ricardo Costa Galo Maldonado Luiz Fernando Leite Tanajura Marinella Patrizia Centemero Áurea Jacob Chaves Andrea Cláudia Sousa Leão Abizaid Rafaela Andrade Penalva Freitas Nancy Toledo Coelho Louis Nakayama Ohe Cely Abboud Fausto Feres
Introduction
The global coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus began in Wuhan, China, in December 2019, and it has affected over 4.4 million people worldwide, with 302,169 deaths as of May 16, 2020. 1
Though respiratory symptoms are the most common presentation of COVID-19, cardiac involvement is a prominent feature of this disease, occurring in 20% to 30% of hospitalized patients and contributing to 40% of deaths. 2-4 COVID-19-related cardiac involvement has been documented by elevations in cardiac biomarkers, and it often presents with changes in the ST-T segment in the 12-lead electrocardiogram (ECG), for which the catheterization laboratory team is often activated. Furthermore, catheterization laboratory activities must continue for care of non-COVID-19 patients who present with genuine acute coronary syndrome (ACS), ST-elevation myocardial infarction (STEMI), and highly symptomatic stable ischemic heart disease.
[…]